<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00123604</url>
  </required_header>
  <id_info>
    <org_study_id>GSK101598</org_study_id>
    <nct_id>NCT00123604</nct_id>
  </id_info>
  <brief_title>Vascular Effects of Carvedilol Versus Metoprolol in Hypertensive Patients With Type 2 Diabetes</brief_title>
  <official_title>Effects of Carvedilol and Metoprolol on Endothelial Function in Hypertensive Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Paul Heart Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Paul Heart Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the vascular effects of two commonly used blood
      pressure medications, carvedilol and metoprolol in hypertensive patients with type 2
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carvedilol and metoprolol are two commonly used blood pressure medications that have both
      been shown to be effective in controlling hypertension. Although in the same drug class,
      preliminary data have shown that these medications may have different vascular effects. This
      study will assess which medication is better at improving artery health independent of their
      blood pressure lowering effects. Artery health will be assessed non-invasively by ultrasound.
      Certain markers of atherosclerosis found in the blood will also be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Dilation</measure>
    <time_frame>change from baseline to 5 months</time_frame>
    <description>Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol, orally, 25 mg, twice daily for five months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol, orally, 200 mg, twice daily for five months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>25 mg twice daily for five months.</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>Coreg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>200 mg twice daily for five months.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Lopressor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-80 years old

          -  Documented history of type 2 diabetes

          -  Stable angiotensin converting enzyme/angiotensin receptor blocker (ACE/ARB) regimen 30
             days before and throughout the study period

          -  Stable anti-diabetic regimen throughout the study period

          -  Body mass index (BMI) between 22-45 kg/m2

          -  HbA1c between 6-9% for patients on anti-diabetic treatment regimen and HbA1c between
             6-8% for patients who are being controlled by diet alone

          -  Screening blood pressure (BP) &gt; 130/80 (average of 3 sitting measurements), with
             current medications

        Exclusion Criteria:

          -  Uncontrollable or symptomatic arrhythmias

          -  Unstable angina

          -  Sick sinus syndrome or second or third degree heart block

          -  Decompensated heart failure

          -  Myocardial infarction (MI) or stroke within 3 months of screening

          -  Bradycardia

          -  Chronic obstructive pulmonary disease (COPD) with required inhaled or oral
             bronchodilators or corticosteroids

          -  Bronchial asthma or related bronchospastic conditions

          -  New onset/diagnosed type 2 diabetes (&lt;3 months)

          -  Clinically significant renal or liver disease (creatinine &gt;2.5 mg/dL)

          -  Endocrine disorders

          -  Use of anorectic or other diet drugs inconsistent with recommendations for type 2
             diabetics

          -  Use of beta-blockers within 3 months of screening

          -  Use of corticosteroids

          -  Systemic disease, including cancer, with reduced life expectancy (&lt;12 months)

          -  Psychological illness/condition that interferes with comprehension of study
             requirements

          -  Use of an investigational drug within 30 days of entry into study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan J Bank, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul Heart Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Paul Heart Clinic</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2005</study_first_posted>
  <results_first_submitted>June 29, 2012</results_first_submitted>
  <results_first_submitted_qc>November 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2014</results_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Paul Heart Clinic</investigator_affiliation>
    <investigator_full_name>Aaron S. Kelly, Ph.D.</investigator_full_name>
    <investigator_title>Senior Research Scientist</investigator_title>
  </responsible_party>
  <keyword>beta-blockers</keyword>
  <keyword>endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occured at medical clinics.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metoprolol</title>
          <description>Metoprolol, orally, 200 mg, once daily</description>
        </group>
        <group group_id="P2">
          <title>Carvedilol</title>
          <description>Carvedilol, orally, 25 mg, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoprolol</title>
          <description>Metoprolol, orally, 200mg, twice daily for five months</description>
        </group>
        <group group_id="B2">
          <title>Carvedilol</title>
          <description>Carvedilol, orally, 25mg, twice daily for five months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.9" spread="9.9"/>
                    <measurement group_id="B2" value="60.9" spread="8.5"/>
                    <measurement group_id="B3" value="61.4" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow Mediated Dilation</title>
        <description>Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion.</description>
        <time_frame>change from baseline to 5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carvedilol</title>
            <description>Carvedilol, orally, 25mg, once daily</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol, orally, 200mg, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Mediated Dilation</title>
          <description>Flow mediated dilation is a measure of endothelial function. It is measured by the percent change in artery diameter (i.e. dilation), pre and post manual artery occlusion.</description>
          <units>percentage of change in dilation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="3.9"/>
                    <measurement group_id="O2" value="4.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metoprolol</title>
          <description>Metoprolol, orally, 200mg, once daily</description>
        </group>
        <group group_id="E2">
          <title>Carvedilol</title>
          <description>Carvedilol, orally, 25 mg, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sample size was relatively small</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Aaron S. Kelly, Ph.D.</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-3492</phone>
      <email>kelly105@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

